profile Bicoll is a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields. The research focus lays on making compounds from natural resources compatible with customers' screening systems for drug discovery and various other fields of application. Bicoll's advanced approach of property-based screening selects promising candidates early on and avoids investment in less promising compounds. Bicoll's products and services are tailored to its customers' needs to accelerate the development process of new pharmaceuticals. The starting material for Bicoll's comprehensive drug discovery services is generated from endemic Asian plant resources, mostly collected in the tropical region of the P.R. China. More than 1/4 of all marketed drugs are derived from small molecules found in plants. With its expertise in high-tech natural products chemistry, Bicoll turns the unparalleled pool of bioactive compounds provided by plants into an accessible source of promising candidates for drug discovery, agro-sciences and nutraceuticals. The Bicoll Group is set-up with two legal entities: Bicoll GmbH in Munich, Germany and since 2001 Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang Hi-Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai. Core competencies and expertise Bicoll's core competencies are based on high performance natural product chemistry for the modern drug discovery process as well as other chemical or life-science related fields. The company's primary products are ready-to-screen small molecule libraries, customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The company utilizes advanced technologies to support its competencies in the fields of structural biology and combinatorial chemistry. Bicoll's high-performance structural elucidation capacities are centered around own developed novel deconvolution techniques and a comprehensive isolation strategy for complex natural products matrix. For Bicoll's in-house research programs in the indication field of oncology, own screening activities are performed with whole cell assays adjusting the apoptosis rate of cells. This novel identified signaling pathway is already patent protected and will be further extended. With this range of competencies, Bicoll is able to enter into alliances with either pharmaceutical or complementary biotech companies. At all pre-clinical stages Bicoll is capable of partially or fully taking over the research part as R&D service provider to support the partners' ongoing research project in the best suitable way.

back to the top